卡培他滨联合奥沙利铂或顺铂一线治疗晚期胃癌临床观察  

Clinical observation of Capecitabine in combination with Oxaliplatin or Cisplatin for first-line treatment of advanced gastric cancer

作　　者：顾术东[1] 刘艳[1] 刘凡[1] 邵棋[1] 沈浮[1] 茅国新[1] 

机构地区：[1]南通大学附属医院肿瘤化疗科,江苏南通226001

出　　处：《中国医药导报》2013年第26期96-98,101,共4页China Medical Herald

基　　金：吴阶平医学基金会临床科研专项资助基金(编号320.6750.1350);先声抗肿瘤治疗专项科研基金(编号CIMF-F-H001-032)

摘　　要：目的 比较卡培他滨联合奥沙利铂与卡培他滨联合顺铂一线治疗晚期胃癌的效果和安全性.方法 收集南通大学附属医院2008年1月～2011年12月收治的晚期胃癌患者69例,分为两组,其中35例接受卡培他滨联合奥沙利铂方案化疗（XELOX组：卡培他滨1000 mg/m2,口服,每天2次,第1～14天；奥沙利铂130 mg/m2,静脉滴注2h,第1天,3周为1个周期）,34例接受卡培他滨联合顺铂方案化疗（XP组：卡培他滨1000 mg/m2,口服,每天2次,第1～14天；顺铂25 mg/m2,静脉滴注,第1～3天）,3周为1个周期.结果 69例患者均可评价疗效及不良反应,XELOX组与XP组的有效率分别为48.6％和41.2％（P＞ 0.05）,疾病控制率分别分别为71.4％和67.6％（P＞ 0.05）,中位疾病进展时间分别为5.9个月和5.1个月（P＞ 0.05）,中位生存时间分别为10.1个月和9.0个月（P＞0.05）.两组不良反应比较,XELOX组外周神经毒性发生率高于XP组（P＜0.05）,其他不良反应XELOX组的发生率均低于XP组,其中恶心呕吐的发生率差异有统计学意义（P＜ 0.05）,XELOX组患者耐受性更好.结论 卡培他滨联合奥沙利铂与卡培他滨联合顺铂一线治疗晚期胃癌的临床效果相当,但不良反应发生率更低.] Objective To evaluate the efficacy and toxicity of Capecitabine in combination with Oxaliplatin or Cis- platin in patients with advanced gastric cancer. Methods 69 patients with advanced gastric cancer in Affiliated Hospi- tal of Nantong University were collected in this study from January 2008 to December 2011, and divided into two groups. 35 patients were treated with Capecitabine combined with Oxaliplatin （XELOX group was treated by Capecitabine 1000 mg/m2 orally twice daily on dj-14 and Oxaliplatin 130 mg,/m2 ivgtt on dl）, and 34 patients were treat- ed with Capecitabine combined with Cisplatin （XP group was treated by Capecitabine lO00 mg/m2 orally twice daily on dt ~4 and Cisplatin 25 mg/m2 ivgtt on dl-3）. Three weeks was a cycle. Results Toxicity and response rate could be evalu- ated in all the patients. In XELOX group and XP group, the response rate was 48.6% and 41.2% （P 〉 0.05）, the dis- ease control rate was 71.4% and 67.6% （P 〉 0.05）, the median time to progress was 5.9 months and 5.1 months （P 〉 0.05） and the median overall survival was 10.1 months and 9.0 months （P 〉 0.05） respectively. In XP group, there were more side effects such as nausea and vomit than in XELOX group, but peripheral neurotoxity was more frequently observed in XELOX group. Conclusion Both chemotherapy regimens are effective in the treatment of advanced gastric cancer, and XELOX is well-tolerated than XP in advanced gastric cancer.

关 键 词：胃癌 卡培他滨 奥沙利铂 顺铂 化疗 

分 类 号：R735.7[医药卫生—肿瘤]